JP2024528986A - Ｈｐｋ１アンタゴニスト及びその使用 - Google Patents
Ｈｐｋ１アンタゴニスト及びその使用 Download PDFInfo
- Publication number
- JP2024528986A JP2024528986A JP2024506668A JP2024506668A JP2024528986A JP 2024528986 A JP2024528986 A JP 2024528986A JP 2024506668 A JP2024506668 A JP 2024506668A JP 2024506668 A JP2024506668 A JP 2024506668A JP 2024528986 A JP2024528986 A JP 2024528986A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- nitrogen
- sulfur
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203890P | 2021-08-03 | 2021-08-03 | |
| US63/203,890 | 2021-08-03 | ||
| US202163264749P | 2021-12-01 | 2021-12-01 | |
| US63/264,749 | 2021-12-01 | ||
| PCT/US2022/074455 WO2023015199A1 (en) | 2021-08-03 | 2022-08-03 | Hpk1 antagonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024528986A true JP2024528986A (ja) | 2024-08-01 |
| JP2024528986A5 JP2024528986A5 (https=) | 2025-08-13 |
| JPWO2023015199A5 JPWO2023015199A5 (https=) | 2025-08-13 |
Family
ID=85156431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506668A Pending JP2024528986A (ja) | 2021-08-03 | 2022-08-03 | Ｈｐｋ１アンタゴニスト及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250011331A1 (https=) |
| EP (1) | EP4380565A4 (https=) |
| JP (1) | JP2024528986A (https=) |
| WO (1) | WO2023015199A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250236619A1 (en) * | 2022-02-23 | 2025-07-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Fused bicyclic compound containing pyrrolinone |
| JP2025519624A (ja) * | 2022-06-10 | 2025-06-26 | 貝達薬業股▲ふん▼有限公司 | Ｈｐｋ１阻害剤およびその医薬における使用 |
| WO2024078448A1 (zh) * | 2022-10-10 | 2024-04-18 | 珠海宇繁生物科技有限责任公司 | 一种hpk1激酶抑制剂及其制备方法和应用 |
| WO2025021181A1 (zh) * | 2023-07-26 | 2025-01-30 | 正大天晴药业集团股份有限公司 | 取代的吡咯啉酮化合物 |
| WO2025096666A1 (en) * | 2023-10-30 | 2025-05-08 | Nimbus Saturn, Inc. | Solid forms of hpk1 antagonists |
| WO2026072991A1 (en) * | 2024-09-26 | 2026-04-02 | Arvinas Operations, Inc. | Hpk1 targeting compounds and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2008047831A1 (ja) * | 2006-10-17 | 2010-02-25 | 協和発酵キリン株式会社 | Ｊａｋ阻害剤 |
| KR101846475B1 (ko) * | 2015-04-27 | 2018-04-09 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
| RS61919B1 (sr) * | 2015-06-25 | 2021-06-30 | Univ Health Network | Inhibitori hpk1 i postupci za njihovo korišćenje |
| WO2018167147A1 (en) * | 2017-03-15 | 2018-09-20 | F. Hoffmann-La Roche Ag | Azaindoles as inhibitors of hpk1 |
| JP7167146B2 (ja) * | 2017-11-06 | 2022-11-08 | ブリストル－マイヤーズ スクイブ カンパニー | Ｈｐｋ１阻害剤として有用なイソフラノン化合物 |
| US11453681B2 (en) * | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CN114945366B (zh) * | 2019-09-13 | 2025-01-07 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| WO2021262684A1 (en) * | 2020-06-22 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
-
2022
- 2022-08-03 WO PCT/US2022/074455 patent/WO2023015199A1/en not_active Ceased
- 2022-08-03 JP JP2024506668A patent/JP2024528986A/ja active Pending
- 2022-08-03 EP EP22854068.8A patent/EP4380565A4/en active Pending
- 2022-08-03 US US18/294,922 patent/US20250011331A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023015199A1 (en) | 2023-02-09 |
| EP4380565A1 (en) | 2024-06-12 |
| EP4380565A4 (en) | 2025-05-21 |
| US20250011331A1 (en) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11679109B2 (en) | SMARCA degraders and uses thereof | |
| WO2021127278A1 (en) | Irak degraders and uses thereof | |
| WO2020010210A1 (en) | Mertk degraders and uses thereof | |
| WO2020251969A1 (en) | Smarca degraders and uses thereof | |
| JP2022547719A (ja) | Ｈｐｋ１アンタゴニストおよびその使用 | |
| AU2021240046A1 (en) | MDM2 degraders and uses thereof | |
| WO2021011868A1 (en) | Irak degraders and uses thereof | |
| WO2021011871A1 (en) | Mertk degraders and uses thereof | |
| US11926625B2 (en) | HPK1 antagonists and uses thereof | |
| JP2024528986A (ja) | Ｈｐｋ１アンタゴニスト及びその使用 | |
| EP4294790A1 (en) | Smarca degraders and uses thereof | |
| US12466841B2 (en) | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | |
| WO2024229393A1 (en) | Hpk1 degraders and uses thereof | |
| EP4288430A1 (en) | Gpr84 antagonists and uses thereof | |
| CN117915912A (zh) | Hpk1拮抗剂和其用途 | |
| EP4646198A1 (en) | Mk2 degraders and uses thereof | |
| CN117377673A (zh) | Hpk1拮抗剂和其用途 | |
| WO2024092011A1 (en) | Irak degraders and uses thereof | |
| EP4452940A1 (en) | Oxer1 antagonists and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250804 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250804 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260417 |